Boston Biomedical Leadership and Directors
Boston Biomedical is wholly owned by Sumitomo Dainippon Pharma Co., Ltd., which is traded on the Tokyo Stock Exchange. Its Board of Directors can be found at here.
Boston Biomedical’s Board of Directors includes executive leadership of Sumitomo Dainippon Pharma Co., Ltd., and an external board member, William J. Rutter, PhD.
Patricia S. AndrewsChief Executive Officer, Boston Biomedical, Inc.
Prior to joining Boston Biomedical, Ms. Andrews served as Executive Vice President and Chief Commercial Officer at Incyte, a U.S.-based biopharmaceutical company, where she led the transition from a clinical-stage research and development organization to a successful commercial enterprise, with the launch of its first-in-class, first-in-disease orphan oncology product. She established the commercial organization and led all functions within sales and marketing. She was also responsible for business development and completed multiple significant product licensing deals for Incyte, including one of the largest licensing deals in biotech in 2009.
Prior to Incyte, Ms. Andrews spent 17 years at Pfizer, culminating in her role as Vice President and General Manager of the U.S. Oncology Business Unit, a $900 million portfolio of products in colorectal cancer, breast cancer, and renal cell carcinoma. Ms. Andrews received her MBA from the University of Michigan and a BA from Brown University.
Kazuo Koshiya, PhDSenior Executive Officer,
Global Head of Oncology,
Sumitomo Dainippon Pharma Co., Ltd.
Since joining Sumitomo Dainippon Pharma in 2011, Dr. Koshiya has led the establishment of the global R&D and business organizations for oncology. Dr. Koshiya will oversee the Company’s overall oncology business, one of its core therapeutics areas.
Prior to Sumitomo Dainippon Pharma, Dr. Koshiya worked for Astellas Pharma for more than 20 years in Japan, the US, and the Netherlands. His responsibilities at Astellas included drug discovery, clinical development, R&D management, and business strategy. From 2007 to 2011, Dr. Koshiya served as Vice President, Product and Portfolio Strategy at Astellas headquarters. One of his achievements during this period was to develop and implement Astellas’ market entry strategy for oncology. Before joining industry, Dr. Koshiya was Assistant Professor of Neurophysiology at Kanazawa University. Dr. Koshiya earned his PhD in neuropharmacology from Tokyo Institute of Technology and a degree in pharmaceutical medicine from the European Center of Pharmaceutical Medicine in Switzerland.
Board of Directors
William J. Rutter, PhDMember, Boston Biomedical Board of Directors
CEO and Founder, Synergenics, LLC
Dr. Rutter is Chairman and Founder of Synergenics, LLC, which owns and controls a portfolio of biotechnology companies at various stages of development.
In his academic career, Dr. Rutter joined the University of California–San Francisco (UCSF) as head of the newly formed department of Biochemistry and Biophysics in 1968, and played a key role in developing UCSF into a major scientific institution. In research, he is particularly known for the discovery of the enzymes involved in the expression of DNA (RNA polymerases), the first cloning of the insulin gene, the cloning of hepatitis B virus (HBV), and formation of an HBV-like particle that provided the basis for a safe and protective vaccine.
With 2 colleagues, Dr. Rutter founded Chiron in 1981, a pioneering biotech firm that developed the first recombinant vaccine (against HBV) with Merck and a process for manufacturing insulin from yeast with Novo-Nordisk. Chiron was the first to clone the AIDS (HIV) virus and to discover, clone, and sequence the hepatitis C virus (HCV). Chiron developed quantitative diagnostic tests for HIV, HBV, and HCV, thus providing the means for eliminating blood contaminated with these viruses, a major contribution to public health worldwide. Chiron developed and promulgated the concept of “viral load” as the basis for determining disease status, as well as the basis for developing and evaluating antivirals and other treatment protocols for these and other diseases.
Prior to Chiron, Dr. Rutter was a consultant to Abbott Laboratories for about 20 years, and a member of the Amgen Scientific Advisory Board. Dr. Rutter’s past board memberships include Novartis, Sangamo Biosciences, Cytokinetics, Nugen, Oscient Pharmaceuticals, and Epitomics.
Dr. Rutter also currently serves on the boards of Eureka Genomics, Apexigen, One Globe, and Cellworks. He is Chairman of the Synergenics companies: Synco Biopartners, ReLIA Diagnostic Systems, Numera Health, Ventria Bioscience, Humabs Biomed, Pathologica, and BioEnergenix.
Dr. Rutter is a member of the National Academy of Sciences and the American Academy of Arts and Sciences, and has received numerous awards for his contributions to science and the biotechnology industry.